Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis

What Was Tested

The paper reports a study of Abaloparatide, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

In this post hoc analysis, the rate of new vertebral fractures for women in ACTIVExtend (N = 1139) was calculated based on baseline and endpoint radiographs for placebo or abaloparatide in ACTIVE and alendronate in ACTIVExtend.

Fracture rates for nonvertebral and clinical fractures were compared based on a Poisson model during 18 months of abaloparatide or placebo treatment in ACTIVE and 18 months of alendronate treatment in ACTIVExtend.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Abaloparatide and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Abaloparatide group a baseline to be compared against.

The timeline in the abstract includes 18 months.

Vertebral fracture rates between abaloparatide and alendronate were compared in a Poisson regression model.

What Was Measured

The subject headings attached to it are Alendronate, Bone Density, Bone Density Conservation Agents, Femur Neck, Lumbar Vertebrae, Osteoporosis, Postmenopausal and Osteoporotic Fractures.

Author keywords: abaloparatide, nonvertebral fractures and vertebral fractures.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Abaloparatide over 18 months.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Abaloparatide compound page, all human trials.